2 No-Brainer Biotech Stocks to Buy Right Now

2 No-Brainer Biotech Stocks to Buy Right Now

Axsome Therapeutics' solid gains of 42% this year came with the hope that its two new products would bring in plenty of revenue in the next few years. Last month, the U.S. Food and Drug Administration (FDA) approved its drug Auvelity for treating major depressive disorder (MDD).